← Nicox S.A. (ALCOX.PA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Nicox S.A. (ALCOX.PA)
Pharmaceutical Preparations · market cap $35M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-04-01
PDUFA
Pipeline
10
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Nicox S.A. (ALCOX.PA) is a French-listed ophthalmic-focused pharmaceutical company with approximately 10 employees and a market capitalization of roughly $37M. Its pipeline spans multiple Phase 2 and Phase 3 assets across glaucoma (NCX 470), blepharitis (NCX 4251, Fluticasone Propionate), and legacy non-ophthalmic programs (Naproxcinod in osteoarthritis, NCX-4016 in intermittent claudication), plus AC-170 0.24% in Phase 3. No upcoming catalysts are currently scheduled and no recent catalyst events have been reported.
The catalyst path
- 2027-04-01PDUFA · NCX 470imp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NCX 4251 | Phase 2 | Blepharitis |
| AC-170 0.24% | Phase 3 | Healthy Subjects |
| Naproxcinod | Phase 3 | Osteoarthritis |
| Naproxcinod 375 mg | Phase 3 | Osteoarthritis |
| NCX-4016 | Phase 2 | Intermittent Claudication |
| NCX 470 0.065% (initial phase of trial) | Phase 3 | Open Angle Glaucoma |
| NCX 470 0.1% | Phase 3 | Open Angle Glaucoma |
| NCX 470 | Phase 3 | Glaucoma, Open-Angle |
| Naproxcinod 375 mg bid | Phase 3 | Osteoarthritis |
| Fluticasone Propionate | Phase 2 | Blepharitis |
Price & technical context
3-month
-13.2%
6-month
-21.4%
12-month
-5.7%
52-wk range
$0.28–$0.51
vs 50-day MA
-9.8%
vs 200-day MA
-13.4%
Realized vol
48.6%
Max drawdown
-54.8%
Daily closes through 2026-10-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALCOX.PA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.